FRIDAY, Aug. 15 (HealthDay News) -- A new drug therapy may help cut down on the lung function loss experienced by patients with moderate to severe chronic obstructive pulmonary disease (COPD), a new study says.
According to the second August issue of American Journal of Respiratory and Critical Care Medicine, a combination of salmeterol, a β-agonist, and fluticasone propiniate, an inhaled cortical steroid, proved a successful therapy in a randomized, double-blind, placebo-controlled trial conducted in 42 countries.